Theratechnologies
LSW completed the new version of Theratechnologies corporate Web site in 2005. At the end of 2006, LSW collaborated once again to develop a media campaign in relation to the presentation of phase III results of the Company’s lead product tesamorelin (TH9507) in patients with HIV-associated lipodystrophy.
Gathering maximum visibility from the media and professional investors in North America were the main challenges for this mandate. In addition, the project was completed in a time frame of approximately two weeks.
LSW combined a variety of interactive tools such as RSS wire, HTML Email campaigns, an online media room, and an active promotion campaign on specialized sites and blogs. Thus LSW was capable of assuring maximum visibility of the event both on the Web as well as in traditional media.